View on Pubmed.gov 25190079 | View on doi.org 10.1101/cshpers...
IL-6 in inflammation, immunity, and disease.
- Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan Department of Immunopathology, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
- Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
- Laboratory of Immune Regulation, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
Abstract
Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase responses, hematopoiesis, and immune reactions. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL-6 plays a pathological effect on chronic inflammation and autoimmunity. For this reason, tocilizumab, a humanized anti-IL-6 receptor antibody was developed. Various clinical trials have since shown the exceptional efficacy of tocilizumab, which resulted in its approval for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Moreover, tocilizumab is expected to be effective for other intractable immune-mediated diseases. In this context, the mechanism for the continual synthesis of IL-6 needs to be elucidated to facilitate the development of more specific therapeutic approaches and analysis of the pathogenesis of specific diseases.
References
Nature. 1988 Jun 23;333(6175):776-8
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9409-14
Cell Mol Immunol. 2009 Oct;6(5):343-52
Proc Natl Acad Sci U S A. 2005 May 10;102(19):6843-8
Cited by 4037 citations (total)
Journal Article
Mutating both and of enteropathogenic E2348/69 attenuates its virulence and induces interleukin 6 .
Electronic publication date March 21, 2023
Jun Bong Lee [...] Jang Won Yoon et al.
Here, we report for the first time that disrupting both and genes in enteropathogenic E2348/69 can attenuate...
Journal Article
Special Focus on the Cellular Anti-Inflammatory Effects of Several Micro-Immunotherapy Formulations: Considerations Regarding Intestinal-, Immune-Axis-Related- and Neuronal-Inflammation Contexts.
Electronic publication date December 21, 2022
Camille Jacques [...] Ilaria Floris et al.
Introduction
Chronic inflammation is a pernicious underlying status, well-known for its contribution to the progressive development of various diseases. In this...
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
Copyright
Copyright © 2014 Cold Spring Harbor Laboratory Press; all rights reserved.